Patents by Inventor Caroline BARELLE

Caroline BARELLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Specific binding molecules
    Patent number: 11919949
    Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 5, 2024
    Assignee: ELASMOGEN LTD
    Inventors: Obinna Ubah, Caroline Barelle, Andrew Porter
  • Single domain binding molecule
    Patent number: 11692025
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 4, 2023
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • ROR1-SPECIFIC ANTIGEN BINDING MOLECULES
    Publication number: 20230203155
    Abstract: The present invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific antigen binding molecules and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).
    Type: Application
    Filed: December 21, 2018
    Publication date: June 29, 2023
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Estelle Grace McLean, Paul Richard Trumper, Jennifer Thom, Timothy Harrison, Graham John Cotton, Caroline Barelle, Andrew Porter, Marina Kovaleva
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20210332116
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: May 17, 2021
    Publication date: October 28, 2021
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • BI-SPECIFIC BINDING MOLECULES
    Publication number: 20210317204
    Abstract: The present invention relates to bi-specific antigen binding molecules and associated fusion proteins and conjugates. In particular, the present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).
    Type: Application
    Filed: December 21, 2018
    Publication date: October 14, 2021
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Estelle Grace McLean, Paul Richard Trumper, Jennifer Thom, Timothy Harrison, Graham John Cotton, Chiara Saladino, Caroline Barelle, Andrew Porter, Marina Kovaleva
  • Single domain binding molecule
    Patent number: 11034756
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 15, 2021
    Assignee: ELASMOGEN LIMITED
    Inventors: Caroline Barelle, Mischa Roland Muller, Valarie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SPECIFIC BINDING MOLECULES
    Publication number: 20200407437
    Abstract: The present invention relates to the formation of multi-domain specific binding molecules comprising VNARs. Specific binding domains that bind to Tumour Necrosis Factor alpha (TNF?) are also provided.
    Type: Application
    Filed: September 27, 2018
    Publication date: December 31, 2020
    Inventors: Obinna UBAH, Caroline BARELLE, Andrew PORTER
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20190194307
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: March 8, 2019
    Publication date: June 27, 2019
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valarie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Single domain binding molecule
    Patent number: 10287341
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 14, 2019
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20170096475
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: September 22, 2016
    Publication date: April 6, 2017
    Applicant: The University Court of the University of Aberdeen
    Inventors: Caroline BARELLE, Mischa Roland MULLER, Valerie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND
  • Single domain binding molecule
    Patent number: 9475870
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 25, 2016
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20160137726
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • SINGLE DOMAIN BINDING MOLECULE
    Publication number: 20130302250
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Inventors: Caroline BARELLE, Mischa MULLER, Valerie CALABRO, Jack BIKKER, John STEVEN, Lioudmila TCHISTIAKOVA, Oleg KOVALENKO, Andrea OLLAND